RCM
DMAA

Radcliffe Capital Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Radcliffe Capital Management’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-546,808
Closed -$5.74M – 465
2026
Q1 		$5.74M Hold
546,808
– – 0.43% 61
2025
Q4 		$5.67M Buy
546,808
+18,708
+4% +$193K 0.31% 65
2025
Q3 		$5.42M Buy
528,100
+401,378
+317% +$4.12M 0.34% 48
2025
Q2 		$1.29M Buy
+126,722
New +$1.28M 0.1% 94

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.69% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.5% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Radcliffe Capital Management's DMAA Position: Q2 2026 in Review

Radcliffe Capital Management sold out of Drugs Made In America Acquisition Corp (DMAA) in Q2 2026, closing a stake of 546,808 shares — an estimated $5.74M sold.

Radcliffe Capital Management first reported a position in DMAA in Q2 2025 and held it in 4 quarters. The position peaked at $5.74M in Q1 2026. 18 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • Radcliffe Capital Management reported no remaining Drugs Made In America Acquisition Corp position as of Q2 2026 after selling out during the quarter.
  • Radcliffe Capital Management sold 546,808 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $5.74M.
  • Radcliffe Capital Management first reported a position in Drugs Made In America Acquisition Corp in Q2 2025 and held it in 4 quarters.
  • Radcliffe Capital Management's Drugs Made In America Acquisition Corp position peaked at $5.74M in Q1 2026.
  • 18 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Radcliffe Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.